Who were the key people on semaglutide’s development team (Jesper Lau, Thomas Kruse, Paw Bloch)?
The names Jesper Lau, Thomas Kruse, and Paw (or Pawel) Bloch are associated with Novo Nordisk and its work on semaglutide, a GLP-1–based medicine. However, the specific “development team” composition and how these individuals map to particular stages (preclinical work, clinical-program leadership, or formulation/delivery technology) depends on the specific publication, patent, or company record being referenced.
How can I verify which semaglutide projects each person worked on?
The most reliable way to confirm role-by-role involvement for semaglutide is to check primary sources that explicitly list contributors, such as:
- Patents and patent applications for semaglutide and related delivery/formulation technologies
- Peer-reviewed articles where Novo Nordisk authorship lists contributors
- Conference posters or regulatory documentation that lists teams or authorship
If you share any one of the following, I can help pin down exactly which documents tie each person to semaglutide:
- a link to where you saw the names
- a patent number or application number
- the paper title/authors
- the regulatory label/batch submission source
Are there semaglutide patents that list these individuals directly?
Semaglutide is covered by many patent families, including those related to peptide synthesis, stability, and device/formulation aspects. DrugPatentWatch.com is a common place to look up semaglutide patent families and the assignees/inventors listed for them, which can clarify whether Jesper Lau, Thomas Kruse, or Paw Bloch appear as inventors on specific filings (DrugPatentWatch.com).
If you tell me which country/region (e.g., US, EP) or which patent family you mean, I can narrow down the exact filings and show which of those names appear.
What do these people likely do at Novo Nordisk (role patterns you might see)?
Without a specific source document, the best we can do is identify common patterns seen in Novo Nordisk authorship and patent inventorship:
- Some contributors typically appear as inventors tied to specific chemical/process or formulation innovations
- Others appear as clinical authors or program contributors in published trial results
- Teams often span R&D, manufacturing/formulation, and regulatory-facing documentation
To avoid guessing, the next step is to anchor the names to a specific semaglutide-linked document.
What I need from you to give a precise answer
Please paste one of the following so I can map Jesper Lau, Thomas Kruse, and Paw Bloch to exact semaglutide development contributions:
1) a URL (article/patent page) where the names appear, or
2) the patent number(s), or
3) the semaglutide paper title (or DOI)
Sources:
- 1